KR101653476B1 - 페녹시에틸 피페리딘 화합물 - Google Patents

페녹시에틸 피페리딘 화합물 Download PDF

Info

Publication number
KR101653476B1
KR101653476B1 KR1020147036137A KR20147036137A KR101653476B1 KR 101653476 B1 KR101653476 B1 KR 101653476B1 KR 1020147036137 A KR1020147036137 A KR 1020147036137A KR 20147036137 A KR20147036137 A KR 20147036137A KR 101653476 B1 KR101653476 B1 KR 101653476B1
Authority
KR
South Korea
Prior art keywords
mmol
methyl
mixture
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147036137A
Other languages
English (en)
Korean (ko)
Other versions
KR20150013893A (ko
Inventor
매튜 앨런 쉬플러
제레미 슐렌버그 요크
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20150013893A publication Critical patent/KR20150013893A/ko
Application granted granted Critical
Publication of KR101653476B1 publication Critical patent/KR101653476B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147036137A 2012-06-29 2013-06-20 페녹시에틸 피페리딘 화합물 Active KR101653476B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
KR20150013893A KR20150013893A (ko) 2015-02-05
KR101653476B1 true KR101653476B1 (ko) 2016-09-01

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147036137A Active KR101653476B1 (ko) 2012-06-29 2013-06-20 페녹시에틸 피페리딘 화합물

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
WO2015094902A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
CN111989311B (zh) * 2019-01-22 2022-03-22 凯复(苏州)生物医药有限公司 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ep4拮抗藥與免疫檢查點抑制物質而進行之癌症治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
US20050250818A1 (en) 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ.ホフマン−ラ ロシュ アーゲー プロスタグランジンアゴニストとしての2−ピペリドン誘導体
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
WO2005105732A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
KR101612971B1 (ko) 2008-05-14 2016-04-15 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
BR112012020236A2 (pt) * 2010-02-22 2016-05-17 Raqualia Pharma Inc uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
LT2619182T (lt) * 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
KR101760164B1 (ko) * 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
US20050250818A1 (en) 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Also Published As

Publication number Publication date
PH12015500009B1 (en) 2020-10-09
CL2014003535A1 (es) 2015-05-08
JO3296B1 (ar) 2018-09-16
WO2014004229A1 (en) 2014-01-03
BR112014031616B1 (pt) 2022-06-21
US20140005226A1 (en) 2014-01-02
AP2014008164A0 (en) 2014-12-31
TWI599561B (zh) 2017-09-21
ME02840B (me) 2018-01-20
SI2867207T1 (sl) 2017-10-30
SG11201408641UA (en) 2015-01-29
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
MA37686B1 (fr) 2017-04-28
CA2875569A1 (en) 2014-01-03
UA114325C2 (uk) 2017-05-25
CA2875569C (en) 2016-04-19
PE20150182A1 (es) 2015-02-13
IL236219A (en) 2017-12-31
IL236219A0 (en) 2015-02-01
MX345324B (es) 2017-01-25
EP2867207B1 (en) 2017-08-09
JP2015522018A (ja) 2015-08-03
HK1203937A1 (en) 2015-11-06
DOP2014000287A (es) 2015-01-31
CY1119425T1 (el) 2018-03-07
AU2013280875A1 (en) 2014-12-04
HRP20171515T1 (hr) 2017-11-17
US9402838B2 (en) 2016-08-02
ZA201408632B (en) 2017-06-28
PL2867207T3 (pl) 2018-01-31
HUE034425T2 (en) 2018-02-28
PT2867207T (pt) 2017-11-01
PH12015500009A1 (en) 2015-03-02
US20150126555A1 (en) 2015-05-07
MX2014015953A (es) 2015-07-17
EA024392B1 (ru) 2016-09-30
DK2867207T3 (en) 2017-09-11
KR20150013893A (ko) 2015-02-05
CN104411684B (zh) 2016-08-24
TW201412717A (zh) 2014-04-01
US8962659B2 (en) 2015-02-24
NZ701933A (en) 2017-01-27
MA37686A1 (fr) 2016-09-30
AU2013280875B2 (en) 2015-09-24
GT201400288A (es) 2015-08-27
CR20140553A (es) 2015-02-04
TN2014000501A1 (en) 2016-03-30
ES2644812T3 (es) 2017-11-30
CO7151507A2 (es) 2014-12-29
EA201492255A1 (ru) 2015-03-31
EP2867207A1 (en) 2015-05-06
AR091429A1 (es) 2015-02-04
BR112014031616A2 (pt) 2017-06-27
MY173878A (en) 2020-02-26
JP6127136B2 (ja) 2017-05-10
LT2867207T (lt) 2017-10-10
RS56452B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
KR101653476B1 (ko) 페녹시에틸 피페리딘 화합물
KR101634032B1 (ko) 디메틸-벤조산 화합물
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
KR101798315B1 (ko) 페녹시에틸 디히드로-1h-이소퀴놀린 화합물
US9000043B2 (en) Phenoxyethoxy compounds
HK1203937B (en) Phenoxyethyl piperidine compounds
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10